Insider Transactions

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Insider Transactions

Date Name Title Type Shares Traded Price Range
Feb 23, 2021
EVP & Chief Financial Officer
EVP & Chief Financial Officer Other acquisition or disposition -- --
Feb 23, 2021
Chief Legal Officer
Chief Legal Officer Other acquisition or disposition -- --
Feb 23, 2021
EVP, COO & CCO
EVP, COO & CCO Other acquisition or disposition -- --
Feb 23, 2021
Director, CEO & President
Director, CEO & President Other acquisition or disposition -- --
Feb 22, 2021
EVP & Chief Financial Officer
EVP & Chief Financial Officer Open market or private sale of non-derivative or derivative security 4,000 $3.73
Feb 22, 2021
Chief Legal Officer
Chief Legal Officer Open market or private sale of non-derivative or derivative security 4,000 $3.73
Feb 22, 2021
EVP, COO & CCO
EVP, COO & CCO Open market or private sale of non-derivative or derivative security 5,000 $3.73
Feb 22, 2021
Director, CEO & President
Director, CEO & President Open market or private sale of non-derivative or derivative security 7,500 $3.73
Feb 19, 2021
EVP & Chief Financial Officer
EVP & Chief Financial Officer Open market or private sale of non-derivative or derivative security 4,672 $3.64
Feb 19, 2021
Chief Legal Officer
Chief Legal Officer Open market or private sale of non-derivative or derivative security 3,295 $3.64
Feb 19, 2021
EVP, COO & CCO
EVP, COO & CCO Open market or private sale of non-derivative or derivative security 5,018 $3.64
Feb 19, 2021
Director, CEO & President
Director, CEO & President Open market or private sale of non-derivative or derivative security 7,257 $3.64
Feb 18, 2021
EVP & Chief Financial Officer
EVP & Chief Financial Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 119,579 --
Feb 18, 2021
EVP & Chief Financial Officer
EVP & Chief Financial Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 144,944 --
Feb 18, 2021
EVP & Chief Financial Officer
EVP & Chief Financial Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 340,618 --
Feb 18, 2021
Chief Medical Officer
Chief Medical Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 110,309 --
Feb 18, 2021
Chief Medical Officer
Chief Medical Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 133,708 --
Feb 18, 2021
Chief Medical Officer
Chief Medical Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 314,213 --
Feb 18, 2021
Chief Legal Officer
Chief Legal Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 110,309 --
Feb 18, 2021
Chief Legal Officer
Chief Legal Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 133,708 --
Feb 18, 2021
Chief Legal Officer
Chief Legal Officer Grant, award or other acquisition pursuant to Rule 16b-3(d) 314,213 --
Feb 18, 2021
EVP, COO & CCO
EVP, COO & CCO Grant, award or other acquisition pursuant to Rule 16b-3(d) 134,410 --
Feb 18, 2021
EVP, COO & CCO
EVP, COO & CCO Grant, award or other acquisition pursuant to Rule 16b-3(d) 162,921 --
Feb 18, 2021
EVP, COO & CCO
EVP, COO & CCO Grant, award or other acquisition pursuant to Rule 16b-3(d) 382,865 --
Feb 18, 2021
Director, CEO & President
Director, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 278,090 --

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.